Evidence map›Paper›PMID 41735712›Full record

ArticleDrug delivery and translational research2026

Quality by design (QbD)-guided development of PEGylated nanostructured lipid carriers of donepezil for intranasal delivery.

Aneri Desai, Nimeet Desai, Lalitkumar K Vora, Pranav Shah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aneri DesaiMaliba Pharmacy College, Uka Tarsadia University, Tarsadi, Bardoli, Gujarat, 394350, India.
Nimeet DesaiDepartment of Eye and Vision Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L7 8TX, UK.
Lalitkumar K VoraSchool of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK. L.vora@qub.ac.uk.
Pranav ShahMaliba Pharmacy College, Uka Tarsadia University, Tarsadi, Bardoli, Gujarat, 394350, India. pranav.shah@utu.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurological disorders (ND) pose a major global health challenge, in large part due to the restrictive nature of the blood-brain barrier (BBB), which prevents most therapeutic agents from reaching the central nervous system (CNS). Intranasal delivery (IN) offers a non-invasive and patient-friendly route to bypass the BBB via the olfactory and trigeminal pathways, but its success requires advanced nanocarrier systems capable of enhancing drug retention, stability, and controlled release. In this study, a Quality by Design (QbD) framework was applied to systematically develop and optimize 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG

Indexed as

DonepezilDrug CarriersNanostructuresPhosphatidylethanolaminesPolyethylene GlycolsAdministration, IntranasalAnimalsDrug Liberation1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)DonepezilDrug CarriersPhosphatidylethanolaminesPolyethylene GlycolsDonepezilIntranasal deliveryNanostructured lipid carriersPEGylationQuality by Design

Identifiers

PMID41735712
PMCPMC13619771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.